

Growth Hormone and Insulin-like Growth Factor I Induce Immunoglobulin (Ig)E and IgG4 Production by Human B Cells

By H. Kimata and M. Fujimoto

From the Department of Pediatrics, Kyoto University Hospital, Kyoto 606, Japan

Summary

We studied the effects of growth hormone (GH), insulin-like growth factor I (IGF-I), IGF-II, and insulin on human immunoglobulin E (IgE) and IgG4 production. GH and IGF-I induced IgE and IgG4 production by normal donors' mononuclear cells (MNC) depleted of sIgE⁺ and sIgG4⁺ B cells without affecting IgM, IgG1, IgG2, IgG3, IgA1, or IgA2 production, whereas IGF-II and insulin failed to do so. GH-induced IgE and IgG4 production was specific, and was not mediated by IGF-I, interleukin 4 (IL-4), or IL-13, since it was blocked by anti-GH antibody (Ab), but not by anti-IGF-I Ab, anti-IL-4 Ab, or anti-IL-13 Ab. Conversely, IGF-I-induced IgE and IgG4 production was blocked by anti-IGF-I Ab, but not by anti-GH Ab, anti-IL-4 Ab, or anti-IL-13 Ab. Moreover, interferon α (IFN- α) or IFN- γ , which counteracted IL-4- and IL-13-induced IgE and IgG4 production, had no effect on induction by GH or IGF-I. In contrast to MNC, GH or IGF-I failed to induce IgE and IgG4 production by purified sIgE⁻, sIgG4⁻ B cells. However, in the presence of anti-CD40 monoclonal antibody (mAb), GH or IGF-I induced IgE and IgG4 production by these cells. Purified sIgE⁺, but not sIgE⁻, B cells from atopic patients spontaneously produced IgE. GH or IGF-I with anti-CD40 mAb failed to enhance IgE production by sIgE⁺ B cells, whereas they induced IgE production by sIgE⁻ B cells. Similarly, whereas GH or IGF-I with anti-CD40 mAb failed to enhance IgG4 production by sIgG4⁺ B cells from atopic patients, they induced IgG4 production by sIgG4⁻ B cells. Again, neither IgE nor IgG4 induction was blocked by anti-IL-4 Ab or anti-IL-13 Ab. These results indicate that GH and IGF-I induce IgE and IgG4 production by class switching in an IL-4- and IL-13-independent mechanism.

In mononuclear cells (MNC), IL-4 induces IgE and IgG4 production, which can be inhibited by IFN- α or IFN- γ (1-3). In contrast, IL-4 alone cannot induce IgE and IgG4 production by purified B cells. However, IL-4 plus anti-CD40 mAb induces IgE and IgG4 production which is not inhibited by IFN- α or IFN- γ (3-6). We and others (7, 8) have reported that T cells from patients with hyper IgE syndrome or atopy secrete IgE-enhancing activity that was not IL-4. We also found that IgE and IgG4 production was modulated by erythropoietin and neuropeptides in an IL-4-, IFN- α -, and IFN- γ -independent fashion (9, 10). These results indicate that there may be another IgE- and IgG4-inducing cytokine(s). Indeed, IL-13 has been shown to induce IgE and IgG4 production in IL-4-independent mechanisms although there are commonalities between the IL-4 and IL-13 receptor, and it is still possible that other factors may be involved in induction of IgE and IgG4 production (11, 12).

We have recently reported that growth hormone (GH) and insulin-like growth factor I (IGF-I) enhanced IgE and IgG4 production by human plasma cell line and plasma cells, whereas IGF-II or insulin failed to do so (13). We therefore studied

whether GH and IGF-I would induce IgE and IgG4 production by normal B cells. Because hormones in serum modulated the GH-induced response, we compared the effects of peptides in serum- and hormone-free medium, DME/F-12 (13, 14). We show that GH and IGF-I, but not IGF-II or insulin, induce IgE and IgG4 production by tonsillar sIgE⁻, sIgG4⁻ B cells in an IL-4- and IL-13-independent fashion.

Materials and Methods

Reagents. The following recombinant human cytokines and Abs were kindly provided by companies described previously (2, 3): IL-4 and rabbit anti-IL-4 Ab (Ono Pharmaceutical Company, Osaka, Japan), IFN- α and IFN- γ (Takeda Chemical Industries, Osaka, Japan), and GH and rabbit anti-GH Ab (Sumitomo Pharmaceuticals, Osaka, Japan). Mouse IgG1 anti-GH receptor mAb (MAB 263) was purchased from Agen Biomedical Ltd. (Qld, Australia) (13). Human recombinant IL-13 was purchased from Pepro Tech Inc. (Rocky Hill, NJ). Human recombinant IGF-I, IGF-II, insulin, rabbit anti-IGF-I Ab, mouse IgG1 anti-IGF-I receptor mAb (α IR-3), mouse IgM anti-CD40 mAb (MA6), rabbit anti-IL-13 Ab, control rabbit IgG, and control mouse IgG1 were purchased from

Cosmo Bio Co. (Tokyo, Japan) (2, 3). The culture medium was a serum- and hormone-free type, DME, supplemented with Ham's Nutrient (DME/F-12) (Sigma Chemical Co., St. Louis, MO), 0.5% BSA, and 50 μ g/ml transferrin (14).

Cell Cultures. Tonsillar MNC were obtained from nonatopic donors (serum IgE level <50 U/ml) and atopic patients (serum IgE level 1,129–13,129 U/ml). MNC were depleted of sIgE⁺ and sIgG4⁺ B cells by panning (10, 15). The percentage of sIgE⁺ and sIgG4⁺ B cells was <0.1%. They were cultured ($3 \times 10^5/0.2$ ml/well) in 96-well U-bottomed microtiter plates (Costar, Cambridge, MA) for 14 d with various factors as described in Results. Highly purified B cells were obtained by SRBC rosetting, followed by L-leucine methyl ester incubation as described previously (10, 15). Purified B cell fractions contained, <1% CD3⁺ T cells, <1% CD14⁺ monocytes, <1% CD16⁺ NK cells and >98% CD20⁺ B cells. Purified B cells were depleted of sIgE⁺ and/or sIgG4⁺ B cells by panning. The percentages, respectively, of sIgE⁺ and sIgG4⁺ B cells in the sIgE⁻ and sIgG4⁻ B cell fractions were <0.1%. Alternatively, sIgE⁺ and sIgG4⁺ B cells were enriched from tonsils of atopic patients by repeated panning. Purified sIgE⁺ and sIgG4⁺ B cell fractions contained >98% sIgE⁺ B cells and >98% sIgG4⁺ B cells, respectively (10, 15). In nonatopic donors, sIgE⁺ and sIgG4⁺ B cell fractions could not be obtained because of paucity of these cells. They were cultured for 14 d as described in Results. Control cultures for the evaluation of preformed Ig were carried out in the presence of cycloheximide (100 μ g/ml). The amount of IgE, IgG subclasses, IgM, and IgA subclasses in the supernatants were determined by ELISA (10, 13).

In some experiments, MNC ($3 \times 10^5/0.2$ ml/well) or B cells ($1 \times 10^5/0.2$ ml/well) were cultured with or without factors for 4 d, and concentrations of GH, IGF-I, or IL-4 were measured by ELISA or RIA (16, 17).

Results

Preliminary experiments have shown that in MNC, medium alone failed to induce IgE (<0.15 ng/ml, $n = 10$) or IgG4 (<0.3 ng/ml, $n = 10$) production, whereas GH and IGF-I at 250 ng/ml induced IgE (4.1 ± 2.7 and 5.2 ± 2.4 ng/ml, respectively, $n = 10$) and IgG4 (33.0 ± 7.4 and 41.7 ± 7.2 ng/ml, respectively, $n = 10$) production. To rule out the possibility that GH- and IGF-I-induced IgE and IgG4 production may result from the expansion of a small sIgE⁺ and sIgG4⁺ B cell population, MNC were depleted of sIgE⁺ and sIgG4⁺ B cells, and they were cultured with peptides. As shown in Fig. 1, A–H, GH and IGF-I induced IgE and IgG4 production in a dose-dependent fashion, whereas they failed to induce IgM, IgG1, IgG2, IgG3, IgA1, and IgA2 production. In contrast, IGF-II and insulin failed to induce IgE (<0.15 ng/ml) or IgG4 (<0.3 ng/ml) or other Ig production (Fig. 1, A–H).

It has been reported that GH-induced stimulation was mediated by endogenously produced IGF-I (17, 18), although we and others (13, 19, 20) have reported the direct enhancing effect of GH. It has also been reported that IL-4 and IL-13 induced IgE and IgG4 production, and that IFN- α and IFN- γ antagonized induction by them (1, 3, 11, 12, 21). Therefore, we compared the inducing effects of GH and IGF-I with those of IL-4 and IL-13. As shown in Fig. 2, GH-induced IgE and IgG4 production was blocked by anti-GH Ab, whereas neither anti-IGF-I Ab nor anti-IL-4 Ab nor anti-IL-13 Ab did




Figure 1. Effects of peptides on Ig production by MNC from nonatopic donors. MNC were depleted of sIgE⁺ and sIgG4⁺ B cells, and were cultured (3×10^5 /well) with medium (\diamond) or increasing concentrations of GH (\bullet), IGF-I (\circ), IGF-II (\blacktriangle), or insulin (\triangle). After 14 d of culture, IgE (A), IgG4 (B), IgM (C), IgG1 (D), IgG2 (E), IgG3 (F), IgA1 (G), and IgA2 (H) production were determined. Values are means \pm 1 SD of triplicate cultures from two experiments.

so. Addition of anti-GH receptor Ab also blocked induction, whereas anti-IGF-I receptor mAb failed to do so (data not shown). Moreover, neither IFN- α nor IFN- γ antagonized the effect of GH (Fig. 2). Conversely, IGF-I-induced IgE and IgG4 production was blocked by anti-IGF-I Ab, whereas none of the anti-GH Ab, anti-IL-4 Ab, anti-IL-13 Ab, IFN- α , or IFN- γ had any effect. Addition of anti-IGF-I receptor mAb also blocked induction whereas anti-GH receptor mAb failed to do so (data not shown). In contrast, IL-4- and IL-13-induced IgE and IgG4 production was blocked by anti-IL-4 Ab and anti-IL-13 Ab, respectively, but not by anti-GH or anti-IGF-I Ab, and induction was antagonized by IFN- α and IFN- γ (Fig. 2).

We also measured GH, IGF-I, and IL-4 concentrations in culture supernatants. To do this, MNC were cultured with or without GH (250 ng/ml) for measurement of IGF-I or IL-4, and, conversely, they were cultured with or without IGF-I (250 ng/ml) for measurement of GH or IL-4. On the other hand, they were cultured with or without IL-4 (1,000 U/ml) for measurement of GH or IGF-I. Cultured supernatants did not contain detectable levels of GH (<10 pg/ml),




Figure 2. Specificity of the effects of GH and IGF-I on IgE and IgG4 production by MNC from nonatopic donors. MNC from nonatopic donors were depleted of sIgE⁺ and sIgG4⁺ B cells, and were cultured (3×10^5 /well) with indicated factors. GH was used at 250 ng/ml, IGF-I at 250 ng/ml, IL-4 at 1,000 U/ml, IL-13 at 50 ng/ml, and all the Abs at 10 μ g/ml, IFN- α at 1,000 U/ml and IFN- γ at 1,000 U/ml. After 14 d of culture, IgE (A) and IgG4 (B) production were determined. Values are means \pm 1 SD of triplicate cultures.

IGF-I (<30 pg/ml), or IL-4 (<40 pg/ml), and addition of GH, IGF-I, or IL-4 failed to induce them.

We next studied the effects of GH and IGF-I on IgE and IgG4 production by purified B cells with or without anti-CD40 mAb (2, 4-6). As shown in Fig. 3, sIgE⁻, sIgG4⁻ B cells failed to produce detectable levels of IgE or IgG4. Neither anti-CD40 mAb nor GH induced them. However, GH plus anti-CD40 mAb induced IgE and IgG4 production which was blocked by anti-GH Ab and anti-GH receptor mAb (data not shown), whereas none of the anti-IGF-I Ab, anti-IGF-I receptor mAb (data not shown), anti-IL-4 Ab, or anti-IL-13 Ab did so. Similarly, IGF-I plus anti-CD40 mAb

induced IgE and IgG4 production, whereas IGF-I alone failed to do so. Induction by IGF-I plus anti-CD40 mAb was specifically blocked by anti-IGF-I Ab or anti-IGF-I receptor mAb (data not shown), but not by anti-GH Ab, anti-GH receptor mAb (data not shown), anti-IL-4 Ab, or anti-IL-13 Ab. Moreover, no detectable levels of GH, IGF-I or IL-4 were induced in cultures of these B cells. In contrast to GH and IGF-I, neither IGF-II plus anti-CD40 mAb nor insulin plus anti-CD40 mAb induced IgE (<0.15 ng/ml) or IgG4 (<0.3 ng/ml) production by sIgE⁻, sIgG4⁻ B cells.

We then studied the effects of GH and IGF-I on spontaneous IgE and IgG4 production by atopic patients' B cells.




Figure 3. Effects of GH and IGF-I on IgE and IgG4 production by B cells from nonatopic donors. B cell from nonatopic donors were depleted of sIgE⁺ and sIgG4⁺ cells (sIgE⁻, sIgG4⁻ B cells), and they were cultured (10^5 /well) with indicated factors. Anti-CD40 mAb were used at 0.1 μ g/ml, GH at 250 ng/ml, IGF-I at 250 ng/ml, and all the Abs at 10 μ g/ml. After 14 d of culture, IgE (■) and IgG4 (□) production were determined. Values are means \pm 1 SD of triplicate cultures.

To do this, sIgE⁺, sIgE⁻, sIgG4⁺, and sIgG4⁻ B cells from atopic patients were separated and cultured with medium or factors. As shown in Fig. 4 A, sIgE⁺ B cells spontaneously produced IgE, which was not enhanced by GH plus anti-CD40 mAb or by IGF-I plus anti-CD40 mAb. (Expts. 1–3). Fig. 4 A also showed that none of anti-GH or anti-IGF-I Ab (Expt. 1), or anti-IL-4 or anti-IL-13 Ab (Expt. 2), or IFN- α or IFN- γ (Expt. 3) affected IgE production by sIgE⁺ B cells. In contrast, sIgE⁻ B cells did not produce IgE with medium alone. However, GH plus anti-CD40 mAb or IGF-I plus anti-CD40 mAb induced IgE production by sIgE⁻ B cells, which was blocked by anti-GH and anti-IGF-I Ab, respectively (Expt. 1), but not by anti-IL-4 or anti-IL-13 Ab (Expt. 2), or by IFN- α or IFN- γ (Expt. 3).

Identical results were observed in IgG4 production by sIgG4⁺ or sIgG4⁻ B cells. As shown in Fig. 4 B, neither GH plus anti-CD40 mAb nor IGF-I plus anti-CD40 mAb affected IgG4 production by sIgG4⁺ B cells, whereas they induced IgG4 production by sIgG4⁻ B cells. Induction by GH and IGF-I was specifically blocked by anti-GH Ab and anti-IGF-I Ab, respectively (Expt. 1), whereas it was not blocked by any of the anti-IL-4 Ab or anti-IL-13 Ab (Expt. 2), or by IFN- α or IFN- γ (Expt. 3).

Discussion

We have demonstrated that GH and IGF-I specifically induced IgE and IgG4 production by normal donors' MNC depleted of sIgE⁺ and sIgG4⁺ B cells, whereas IGF-II and insulin failed to do so. The detailed mechanisms of differential effects of these peptides are currently under investiga-

tion. However, this is not surprising. We and others (13, 22, 23) have reported that GH and IGF-I stimulated plasma cells, pre-T cells, and neutrophils, whereas IGF-II or insulin were either less stimulatory or without effect.

It has been reported that GH-induced stimulation was mediated by IGF-I, although a direct stimulating effect of GH was also reported (13, 17–20). Moreover, IL-4 and IL-13 have been shown to induce IgE and IgG4 production (1–3, 11, 12). However, our results indicate that GH effect was specific, and was not mediated by IGF-I, IL-4, or IL-13, because GH-induced IgE and IgG4 production was blocked by anti-GH Ab, but not by anti-IGF-I Ab, anti-IL-4 Ab, or anti-IL-13 Ab. In addition, whereas IFN- α and IFN- γ inhibited IL-4- and IL-13-induced IgE and IgG4 production, they had no effect on GH- or IGF-I-induced IgE and IgG4 production. Furthermore, no IGF-I or IL-4 was detectable in the culture supernatants with GH. Conversely, IGF-I-induced induction was not mediated by GH, IL-4, or IL-13, because it was blocked by anti-IGF-I Ab, but not by anti-GH Ab, anti-IL-4, Ab or anti-IL-13 Ab. Moreover, no GH or IL-4 was produced by IGF-I.

GH and IGF-I also induced IgE and IgG4 production by normal donors' sIgE⁻, sIgG4⁻ B cells in the presence, but not absence, of anti-CD40 mAb. Again, this induction was specific to each peptide. These results indicate that GH- and IGF-I-induced IgE and IgG4 production was due to switching but not to expansion of sIgE⁺ and sIgG4⁺ B cells. This was directly shown by using sIgE⁺, sIgG4⁺, sIgE⁻, or sIgG4⁻ B cells from atopic patients. Whereas GH plus anti-CD40 mAb or IGF-I plus anti-CD40 mAb induced IgE and IgG4 production by sIgE⁻ and sIgG4⁻ B cells, respectively, they




Figure 4. Effects of GH and IGF-I on IgE and IgG4 production by sIg⁺ and sIg⁻ B cells from atopic patients. Purified sIgE⁺ or sIgE⁻ (A), and sIgG4⁺ or sIgG4⁻ (B) B cells from atopic patients were cultured (2×10^4 /well) with indicated factors. Anti-CD40 mAb was used at 0.1 μ g/ml, GH at 250 ng/ml, IGF-I at 250 ng/ml, all the Abs at 10 μ g/ml, IFN- α at 1,000 U/ml, and IFN- γ at 1,000 U/ml. After 14 d of culture, IgE (A) and IgG4 (B) production were determined. Values are means \pm 1 SD of triplicate cultures.

failed to do so by sIgE⁺ and sIgG4⁺ B cells, respectively.

The in vivo influence of GH and IGF-I remains to be elucidated. However, it has been reported that alveolar macrophages from patients with lung disease produced IGF-I, and that IgE concentrations in bronchoalveolar lavage (BAL) fluid was elevated in those patients (24, 25). In accordance with this, we have found that GH and IGF-I concentrations in BAL fluid were elevated in asthmatic patients: GH and IGF-I concentrations in BAL fluid in asthmatic patients ($n = 5$) were 45 ± 12 and 61 ± 10 pg/ml ($n = 5$), respec-

tively, whereas those in normal donors ($n = 5$) were <10 and <30 pg/ml, respectively. Moreover, there are cases with IgE deficiency and GH deficiency and low serum levels of IGF-I (26).

GH and IGF-I seem to be excellent reagents in the study of IgE and IgG4 regulation. We and others (1-3, 5, 21) have reported that various factors modulate IL-4-induced IgE and IgG4 production. The interaction of GH and IGF-I with those factors is currently under investigation.

This work was supported by a grant from the Ministry of Health and Welfare and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan.

Address correspondence to Dr. H. Kimata, Department of Pediatrics, Kyoto University, 54, Kawaharacho, Shogoin, Sakyo-Ku, Kyoto 606, Japan.

Received for publication 15 March 1994.

References

1. Péne, J., F. Rousset, F. Brière, I. Chrétien, J.-Y. Bonnefoy, H. Spits, T. Yokota, N. Arai, K. Arai, J. Banchereau, and J.E. de Vries. 1988. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferon γ and α and prostaglandin E₂. *Proc. Natl. Acad. Sci. USA.* 85:6880.
2. Kimata, H., A. Yoshida, C. Ishioka, I. Lindley, and H. Mikawa. 1992. Interleukin 8 (IL-8) selectively inhibits immunoglobulin E production induced by IL-4 in human B cells. *J. Exp. Med.* 176:1227.
3. Kimata, H., A. Yoshida, C. Ishioka, and H. Mikawa. 1992. Differential effect of vasoactive intestinal peptide, somatostatin, and substance P on human IgE and IgG subclass production. *Cell. Immunol.* 144:429.
4. Jabara, H.H., S.M. Fu, R.S. Geha, and D. Vercelli. 1990. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. *J. Exp. Med.* 172:1861.
5. Zhang, K., E.A. Clark, and A. Saxon. 1991. CD40 stimulation provides an IFN- γ -independent and IL-4-dependent differentiation signal directly to human B cells for IgE production. *J. Immunol.* 146:1836.
6. Gascan, H., J.-F. Gauchat, G. Aversa, P.E. Vlasselear, and J.E. de Vries. 1991. Anti-CD40 monoclonal antibodies or CD4⁺ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. *J. Immunol.* 147:8.
7. Kimata, H., E.H. Sherr, and A. Saxon. 1988. Human natural killer (NK) cells produce a late-acting B-cell differentiation activity. *J. Clin. Immunol.* 8:381.
8. Zhang, X., B. Polla, C. Hauser, and R.H. Zubler. 1992. T cells from atopic individuals produce IgE-enhancing activity incompletely blocked by anti-interleukin-4 antibody. *Eur. J. Immunol.* 22:829.
9. Kimata, H., A. Yoshida, C. Ishioka, and H. Mikawa. 1991. Effect of recombinant human erythropoietin on human IgE production *in vitro*. *Clin. Exp. Immunol.* 83:483.
10. Kimata, H., A. Yoshida, F. Masayuki, and H. Mikawa. 1993. Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. *J. Immunol.* 150:4630.
11. Punnonen, J., G. Aversa, B.G. Cocks, A.N.J. McKenzie, S. Menson, G. Zurawski, R. de Waal Malefyt, and J.E. de Vries. 1993. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. *Proc. Natl. Acad. Sci. USA.* 90:3730.
12. Aversa, G., J. Punnonen, B.G. Cocks, R. de Waal Malefyt, F. Vega, Jr., S.M. Zurawski, G. Zurawski, and J.E. de Vries. 1993. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. *J. Exp. Med.* 178:2213.
13. Kimata, H., and A. Yoshida. 1994. Differential effect of growth hormone, and insulin-like growth factor-I, insulin-like growth factor-II, and insulin on Ig production and growth in human plasma cells. *Blood.* 83:121.
14. Yoshida, A., C. Ishioka, H. Kimata, and H. Mikawa. 1992. Recombinant human growth hormone stimulates B cell immunoglobulin synthesis and proliferation in serum-free medium. *Acta. Endocrinol.* 126:524.
15. Kimata, H., and H. Mikawa. 1993. Nedocromil sodium selectively inhibits IgE and IgG4 production in human B cells stimulated with IL-4. *J. Immunol.* 151:6723.
16. Hattori, N., A. Shimatsu, M. Sugita, S. Kumagai, and H. Imura. 1990. Immunoreactive growth hormone (GH) secretion by human lymphocyte: Augmented release by GH. *Biochem. Biophys. Res. Commun.* 168:396.
17. Merimee, T.J., M.B. Grant, C.M. Broder, and L.L. Cavall-Sforza. 1989. Insulin-like growth factor secretion by human B-lymphocytes: A comparison of cells from normal and pygmy subjects. *J. Clin. Endocrinol. & Metabol.* 69:978.
18. Geffner, M.E., N. Bersch, B.M. Lippe, R.G. Rosenfeld, R.L. Hintz, and D.W. Golde. 1990. Growth hormone mediates the growth of T-lymphoblast cell lines via locally generated insulin-like growth factor-I. *J. Clin. Endocrinol. & Metabol.* 71:464.

19. Merchav, S., I. Tatarsky, and Z. Hochberg. 1988. Enhancement of erythropoiesis *in vitro* by human growth hormone is mediated by insulin-like growth factor I. *Br. J. Hematol.* 70:267.
20. Doi, T., L.J. Striker, C. Quaife, F.G. Conti, R. Palmiter, R. Behringer, R.L. Brinster, and G.E. Striker. 1988. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone-releasing factor but not in those expressing insulin-like growth factor-I. *Am. J. Pathol.* 131:398.
21. Rousset, F., J. Robert, M. Andary, J.-P. Bonnin, G. Souillet, I. Chrétien, F. Brière, J. Pène, and J.E. de Vries. 1991. Shifts in interleukin-4 and interferon- γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. *J. Allergy. Clin. Immunol.* 87:58.
22. Gjerset, R.A., J.O. Yeargin, S.K. Volkman, V. Vila, J. Arya, and M. Haas. 1990. Insulin-like growth factor-I supports proliferation of autocrine thymic lymphoma cells with a pre-T cell phenotype. *J. Immunol.* 145:3497.
23. Fu, Y.-K., S. Arkins, B.S. Wang, and K.W. Kelly. 1991. A novel role of growth hormone and insulin-like growth factor-I. Priming neutrophil for superoxide anion secretion. *J. Immunol.* 146:1602.
24. Rom, W.N., P. Basset, G.A. Fells, T. Nukiwa, B.C. Trapnell, and R.G. Crystal. 1988. Alveolar macrophage release an insulin-like growth factor I-type molecule. *J. Clin. Invest.* 82:1685.
25. Diaz, P., F.R. Galleguillos, M.C. Gonzalez, C.F.A. Pantin, and A.B. Kay. Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. *J. Allergy. Clin. Immunol.* 74:41.
26. Fleisher, T.A., R.M. White, S. Broder, S.P. Nissley, R.M. Blease, J.J. Mulvihill, G. Olive, and T.A. Waldmann. 1980. X-linked hypogammaglobulinemia and isolated growth hormone deficiency. *N. Engl. J. Med.* 302:1429.